Introduction:
Leading pharmaceutical company reported a 142% YoY increase in net profit for Q3FY25, reaching ₹17.2 crore. Revenue surged 35% YoY to ₹106.4 crore, driven by strong sales and operational efficiency, while EBITDA grew by 92%.
Also Read: Stocks To Watch For Budget 2025
Share price movement of Senores Pharmaceuticals:
On January 23, 2025, Senores Pharmaceuticals Ltd. opened at ₹508.50, up 2.13% from its previous close of ₹497.90. The stock reached a high of ₹584.35 (17.34%) and a low of ₹499.85. By 3:25 PM, it traded at ₹542.00, an 8.86% increase, with a market cap of ₹2,496.10 crore.
Senores Pharmaceuticals Reports 142% Surge in Q3 Profit:
Senores Pharmaceuticals posted a net profit of ₹17.2 crore for Q3FY25, reflecting a significant 142% increase from ₹7.1 crore in Q3FY24. This growth highlights the company’s improved financial performance over the year.
The company’s revenue surged 35% YoY to ₹106.4 crore in Q3FY25, compared to ₹78.7 crore in the same quarter last year. This robust revenue growth was driven by higher sales and operational efficiency.
Operating performance also saw a substantial boost, with EBITDA rising 92% YoY to ₹29.1 crore, up from ₹15.2 crore in Q3FY24. Consequently, the EBITDA margin expanded to 27.3%, compared to 19.2% in Q3FY24, signaling strong cost management.
Recent news on Senores Pharmaceuticals:
As of December 30, 2024, Senores Pharmaceuticals made a strong stock market debut, listing at ₹600 on the NSE, a 53.45% premium over its issue price. On the BSE, it debuted at ₹593.70, a 52% premium.
Stock performance of Senores Pharmaceuticals for Period of 1 week:
Over the past week, Senores Pharmaceuticals saw a decline of 2.41% in its stock price. Despite the recent dip, the company has shown strong growth in the market since its debut, maintaining a solid performance overall.
Also Read: Best Sectors To Watch For Budget 2025
Shareholding pattern of Senores Pharmaceuticals:
| All values in % | Dec 2024 |
| Promoter | 45.80% |
| FII | 4.30% |
| DII | 11.80% |
| Public | 38.20% |
About Senores Pharmaceuticals:
Senores Pharmaceuticals Ltd. (NSE: SENORES) is a global, research-driven pharmaceutical company specializing in generics, critical care injectables, and APIs. With manufacturing facilities in the US and India, it serves over 40 countries and holds numerous regulatory approvals.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
